- CVS Health appoints Brian Newman as CFO in strategic leadership reshuffle.
- Analysts offer a one-year price target indicating potential growth for CVS stock.
- GuruFocus projects a significant upside based on GF Value estimates.
CVS Health (CVS, Financial) has made a significant move by appointing Brian Newman, formerly of UPS, as its new Chief Financial Officer, effective April 21, 2025. This leadership change is a part of CVS Health's broader strategy to enhance its financial performance following a year where it missed earnings targets in 2024. Despite these challenges, the company maintains a positive outlook and aims to meet its 2025 financial projections.
Analyst Price Targets and Recommendations
According to the forecasts of 24 analysts covering CVS Health Corp (CVS, Financial), the average one-year price target stands at $70.98, with forecasts ranging from a high of $80.00 to a low of $48.01. This average target suggests a potential upside of 5.34% from the current stock price of $67.38. Investors can explore more detailed projections on the CVS Health Corp (CVS) Forecast page.
Moreover, among 29 brokerage firms, CVS Health Corp (CVS, Financial) receives an average brokerage recommendation of 2.2, which translates to an "Outperform" rating. This scale ranges from 1, indicating a Strong Buy, to 5, signifying a Sell recommendation, showcasing analysts' confidence in the company's future performance.
GuruFocus GF Value Insights
GuruFocus provides a compelling valuation perspective with its GF Value estimate for CVS Health Corp (CVS, Financial), pegged at $87.80 over the next year. This suggests a notable upside of 30.31% from the current trading price of $67.38. The GF Value is a proprietary metric that evaluates the fair value of a stock by considering its historical trading multiples, past business growth, and future performance projections. Investors looking for more comprehensive insights can visit the CVS Health Corp (CVS) Summary page.
